Biljana Stanković

Viši naučni saradnik
Laboratorija za molekularnu biomedicinu

Institut za molekularnu genetiku i genetičko inženjerstvo (IMGGI),
Univerzitet u Beogradu,

Vojvode Stepe 444a, 11042 Beograd 152, Srbija
Mob:   +381 65 397 64 45
Tel:     +381 11 397 64 45
Fax: +381 11 397 58 08
E-mail: biljana.stankovic@imgge.bg.ac.rs                 

OBRAZOVANJE

2019-2021 – Kratak program studija „Bioinformatika za biologe“ na Računarskom fakultetu Univerziteta Union u Beogradu
2015 – doktor bioloških nauka, Biološki fakultet (BF), Univerzitet u Beogradu (UB), (naslov teze: "Molekularni markeri hronične inflamacije i apoptoze kod inflamatornih bolesti creva")
2009 – Diplomirani molekularni biolog i fiziolog, BF, UB

ISTRAŽIVAČKO ISKUSTVO

2021 - Viši naučni saradnik, Institut za molekularnu genetiku i genetičko inženjerstvo (IMGGI), UB
2016 – Naučni saradnik, Institut za molekularnu genetiku i genetičko inženjerstvo (IMGGI), UB
2011 – Istraživač saradnik, IMGGI, UB 
2010 – Istraživač pripravnik, IMGGI, UB

RADNO ISKUSTVO

 

Nacionalni projekti

  • „Retke bolesti: molekularna patofiziologija, dijagnostički i terapijski modaliteti i socijalni, etički i pravni aspekti“, potprojekat: „Kronova bolest: molekularnogenetički markeri poremećaja inflamacije i apoptoze i farmakogenetički pristup u modulaciji terapije“ (MPNTR, III 41004, 2011-2019) - učesnik
  • „Strukturalni elementi genoma u modulaciji fenotipa“ (MNTRS, 143051, 2006-2010) – učesnik
  • Projekat „Nutrigenetika i status vitamina D, cinka i selena u srpskoj populaciji: da li smo spremni za COVID-19?, finansiran od strane programa Pokreni se za nauku (2020-2021) - učesnik

Međunarodni projekti

  • COST akcija: CA18240 – “ADHEsion GPCR Network: Research and Implementation Set the path for future Exploration”, 2019-2023 - član za Srbiju i rukovodilac 1. radne grupe/radnog paketa
  • Projekat „Towards personalized treatment for inflammatory bowel disease: pursuit for biomarkers of glucocorticoid drug response“, Labena Grant Challenge 2020 – rukovodilac
  • Bilateralni projekat naučno-tehnološke saradnje između Republike Srbije i Republike Slovenije 2014-2015, pod nazivom: „Farmakogenomički markeri u imunosupresivnoj i imunomodulatorskoj terapiji: od validiranih markera do kitova za genotipizaciju i kliničkih algoritama“ (451-03-3095/2014-09/45, 2014-2015) - učesnik
  • Noć istraživača - Science in Motion for Friday Night Commotion “SCIMFONICOM” 2018-19 (H2020-MSCANIGHT-2018-818747) - učesnik

OSTALE AKTIVNOSTI

  • 2020 – Volonterski rad u nacionalnoj laboratoriji za molekularnu detekciju infektivnih agenasa „Vatreno oko“, Kliničkog centra Srbije
  • 2016-2020 - Predavač na doktorskim studijama na Biološkom fakultetu UB u okviru studijskog programa molekularna biologija (predmet „ Molekularna genetika bolesti čoveka“)
  • 2018 - Član organizacionog komiteta kongresa „Belgrade Bioinformatics Conference“ (BelBi2018) u Beogradu
  • 2011-2019 - Učesnik u brojnim manifestacijama sa ciljem edukacije i popularizacije nauke (u organizaciji projekata “Mala škola DNKlogije” 2009-2011, MPNTR RS, i Evropskog projekta Noć Istraživača)

OBLAST NAUČNOG INTERESOVANJA

Identifikacija molekularnih, farmakogenomskih i farmakotranskriptomskih markera kod inflamatornih bolesti creva, Kronove bolesti (KB) i ulceroznog kolitisa. Genetička osnova inflamatornih bolesti povezanih za poremećenom crevnom homeostazom. Farmakogenomika i farmakotranskriptomika lekova koji se koriste u terapiji dečje akutne limfoblastne leukemije. Primena biostatistike i bioinformatike u biomedicini. Izučavanje genetičkih faktora rizika za teže oblike bolesti COVID-19.

ODABRANI NAUČNI RADOVI

  1. Stankovic B, Dragasevic S, Klaassen K, Kotur N, Srzentic Drazilov S, Zukic B, Sokic Milutinovic A, Milovanovic T, Lukic S, Popovic D, Pavlovic S, Nikcevic G. Exploring inflammatory and apoptotic signatures in distinct Crohn's disease phenotypes: Way towards molecular stratification of patients and targeted therapy. Pathol Res Pract. 2020 Jun;216(6):152945. https://pubmed.ncbi.nlm.nih.gov/32279918/
  2. Stankovic B, Dragasevic S, Popovic D, Zukic B, Kotur N, Sokic-Milutinovic A, Alempijevic T, Lukic S, Milosavljevic T, Nikcevic G, Pavlovic S. Variations in inflammatory genes as molecular markers for prediction of inflammatory bowel disease occurrence. J Dig Dis. 2015 Dec; 16(12):723-33. https://www.ncbi.nlm.nih.gov/pubmed/26316104
  3. Dragasevic S, Stankovic B, Sokic-Milutinovic A, Milosavljevic T, Milovanovic T, Lukic S, Drazilov SS, Klaassen K, Kotur N, Pavlovic S, Popovic D. Importance of TLR9-IL23-IL17 axis in inflammatory bowel disease development: Gene expression profiling study. Clin Immunol. 2018;197:86-95. https://pubmed.ncbi.nlm.nih.gov/30193869/
  4. Lucafò M, Stankovic B, Kotur N, Silvestre AD, Martelossi S, Ventura A, Zukic B, Pavlovic S, Decorti G. Pharmacotranscriptomic biomarkers in glucocorticoid treatment of pediatric inflammatory bowel disease. Curr Med Chem. 2018; 25(24):2855-2871. https://pubmed.ncbi.nlm.nih.gov/28933291/
  5. Bojović K, Stanković B, Kotur N, Krstić-Milošević D, Gašić V, Pavlović S, Zukić B, Ignjatović Đ. Genetic predictors of celiac disease, lactose intolerance, and vitamin D function and presence of peptide morphins in urine of children with neurodevelopmental disorders. Nutr Neurosci. 2019; 22(1):40-50. https://pubmed.ncbi.nlm.nih.gov/28738753/
  6. Marina Mihaljevic, Dusanka Franic, Ivan Soldatovic, Iva Lukic, Sanja Andric Petrovic, Tijana Mirjanic, Biljana Stankovic, Branka Zukic, Katarina Zeljic, Vladimir Gasic, Ivana Novakovic, Sonja Pavlovic, Miroslav Adzic, Nadja P. Maric. The FKBP5 genotype and childhood trauma effects on FKBP5 DNA methylation in patients with psychosis, their unaffected siblings, and healthy controls, Psychoneuroendocrinology, 2021, 105205. https://doi.org/10.1016/j.psyneuen.2021.105205.
  7. Dragasevic S, Stankovic B, Kotur N, Sokic-Milutinovic A, Milovanovic T, Lukic S, Milosavljevic T, Srzentic Drazilov S, Klaassen K, Pavlovic S, Popovic D. Metabolic Syndrome in Inflammatory Bowel Disease: Association with Genetic Markers of Obesity and Inflammation. Metab Syndr Relat Disord. 2020;18(1):31-38. https://pubmed.ncbi.nlm.nih.gov/31750766/
  8. Stanković B, Radlović N, Leković Z, Ristić D, Radlović V, Nikčević G, Kotur N, Vučićević K, Kostić T, Pavlović S, Zukic B. HLA genotyping in pediatric celiac disease patients. Bosn J Basic Med Sci. 2014 Aug 16; 14(3):171-6. http://www.ncbi.nlm.nih.gov/pubmed/25172978
  9. Balasopoulou A, Stanković B, Panagiotara A, Nikčevic G, Peters BA, John A, Mendrinou E, Stratopoulos A, Legaki AI, Stathakopoulou V, Tsolia A, Govaris N, Govari S, Zagoriti Z, Poulas K, Kanariou M, Constantinidou N, Krini M, Spanou K, Radlovic N, Ali BR, Borg J, Drmanac R, Chrousos G, Pavlovic S, Roma E, Zukic B, Patrinos GP, Katsila T. Novel genetic risk variants for pediatric celiac disease. Hum Genomics. 2016 Oct 24; 10(1):34. https://www.ncbi.nlm.nih.gov/pubmed/27836013
  10. Kotur N, Stankovic B, Kassela K, Georgitsi M, Vicha A, Leontari I, Dokmanovic L, Janic D, Krstovski N, Klaassen K, Radmilovic M, Stojiljkovic M, Nikcevic G, Simeonidis A, Sivolapenko G, Pavlovic S, Patrinos GP, Zukic B. 6-mercaptopurine influences TPMT gene transcription in a TPMT gene promoter variable number of tandem repeats-dependent manner. Pharmacogenomics. 2012; 13(3): 283-95. https://www.ncbi.nlm.nih.gov/pubmed/22304581
  11. Kotur N, Dokmanovic L, Janic D, Stankovic B, Krstovski N, Tosic N, Katsila T, Patrinos GP, Zukic B, Pavlovic S. TPMT gene expression is increased during maintenance therapy in childhood acute lymphoblastic leukemia patients in a TPMT gene promoter variable number of tandem repeat-dependent manner. Pharmacogenomics. 2015; 16(15):1701-12. https://www.ncbi.nlm.nih.gov/pubmed/26411491
  12. Kotur N, Lazic J, Ristivojevic B, Stankovic B, Gasic V, Dokmanovic L, Krstovski N, Milosevic G, Janic D, Zukic B, Pavlovic S. Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment. Genes (Basel). 2020 Apr 24;11(4):468. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230684/
  13. Pavlovic S, Kotur N, Stankovic B, Gasic V, Lucafo M, Decorti G, Zukic B. Clinical Application of Thiopurine Pharmacogenomics in Pediatrics. Curr Drug Metab. 2020;21(1):53-62. https://pubmed.ncbi.nlm.nih.gov/32124692/
  14. Pavlovic S, Kotur N, Stankovic B, Zukic B, Gasic V, Dokmanovic L. Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: Paving the Way to Personalized Treatment. Genes (Basel). Genes (Basel). 2019;10(3):191. https://pubmed.ncbi.nlm.nih.gov/30832275/
  15. Klaassen K, Stankovic B, Zukic B, Kotur N, Gasic V, Pavlovic S, Stojiljkovic M. Functional prediction and comparative population analysis of variants in genes for proteases and innate immunity related to SARS-CoV-2 infection. Infect Genet Evol 2020; 84:104498. https://pubmed.ncbi.nlm.nih.gov/32771700/
  16. Stanković B, Kotur N, Gašić V, Klaassen K, Ristivojević B, Stojiljković M, Pavlović S, Zukić B. Pharmacogenomics landscape of COVID-19 therapy response in Serbian population and comparison with worldwide populations. J Med Biochem. 2020 Oct 2;39(4):488-499. https://pubmed.ncbi.nlm.nih.gov/33312066/

Please publish modules in offcanvas position.